Background The newly approved biologics and Janus kinase inhibitors (JAKi) for pediatric atopic dermatitis (AD) offer additional options for clinical treatment. However, the efficacy and safety differ
Trialstreamer annotated collection of RCTs. This respository contains baseline files (large), and subsequent updates (daily for PubMed, weekly for ICTRP).
